Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also offers VRDN-006 that is in Phase 1 clinical trial and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Viridian Therapeutics Inc.

Viridian Metals Inc ( ($TSE:VRDN) ) has provided an announcement. Viridian Metals Inc., a critical metals explorer listed on the CSE, has secured t...

Viridian Metals Wins Maximum JEA Grant and Switches to Semi-Annual Reporting

RBC Capital analyst Lisa Walter maintained a Buy rating on Viridian Therapeutics yesterday and set a price target of $30.00. The company’s shares c...

RBC Capital Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Soleno Therapeutics (SLNO) and Viridian Therapeutics (VRDN). Sole...

Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO) and Viridian Therapeutics (VRDN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pelthos Therapeutics (PTHS), IDEAYA Biosciences (IDY...

Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (PTHS), IDEAYA Biosciences (IDYA) and Viridian Therapeutics (VRDN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viridian Therapeutics (VRDN) and Bristol-Myers Squ...

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Bristol-Myers Squibb (BMY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Jasper Therapeutics (JSPR), Alto Neuroscience, Inc...

Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Alto Neuroscience, Inc. (ANRO) and Viridian Therapeutics (VRDN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Phreesia (PHR), Viridian Therapeutics (VRDN) and Orthofix Medical...

Analysts Conflicted on These Healthcare Names: Phreesia (PHR), Viridian Therapeutics (VRDN) and Orthofix Medical (OFIX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lipocine (LPCN), Viridian Therapeutics (VRDN) and Incyte (INCY). ...

Market Cap	$1.59B	P/E Ratio	N/A
52W High	$34.29	52W Low	$9.90
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	22.8%	52W Position	17.7%
Overall Score	47	Value Score	60
Quality Score	42	Technical Score	40

EPS Current Est	$-3.56	EPS Next Est	$-1.89
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VRDN	$14.21	+1.79%	2.90M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VRDN	$14.21	+1.8%	2.90M
3
4
5
6

VRDN

VRDN

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Viridian Therapeutics Inc. Data in Excel

Get Viridian Therapeutics Inc. Data in Excel